260
Participants
Start Date
June 30, 2016
Primary Completion Date
December 31, 2019
Study Completion Date
December 31, 2019
Sugammadex
Sugammadex will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Placebo
Placebo will be administered intravenously at 2 mg/kg after routine reversal of anesthesia is performed and subject is extubated.
Mayo Clinic Florida, Jacksonville
The University of Texas, UTHealth, Houston
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
University of Texas
OTHER
Respiratory Motion, Inc.
INDUSTRY
Mayo Clinic
OTHER